Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

BACKGROUND: To understand the extent to which a large-scale healthcare claims database (DB) captures the safety profile of eribulin mesylate (Halaven(®), Eisai Co., Ltd., Japan), we compared patient characteristics, drug use, and adverse events (AEs) between data for patients treated with eribulin r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Yukinori, Matsuoka, Toshiyuki, Ohashi, Satoshi, Koga, Tadashi, Toyoda, Tetsumi, Ishii, Mika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423272/
https://www.ncbi.nlm.nih.gov/pubmed/30847841
http://dx.doi.org/10.1007/s40801-019-0150-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423272/
https://www.ncbi.nlm.nih.gov/pubmed/30847841
http://dx.doi.org/10.1007/s40801-019-0150-8

Ejemplares similares